A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG

Inclusion Criteria: * Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures. * Male or female adults aged 18 to 75 years at the time of signing the ICF. * Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \>50% of the pons volume, with diffuse brainstem enlargement. * Karnofsky Performance Status (KPS) score ≥ 60. * Expected survival time ≥ 3 months. Exclusion Criteria: * Individuals with extracranial metastases. * Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination. * Active hemorrhage detected on cranial MRI scan prior to enrollment. * Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants). * Prior receipt of oncolytic virus therapy or other gene therapy agents.